Barry Teobald

Barry Teobald is an accomplished medicinal chemist with extensive experience in the pharmaceutical industry. Most recently, Barry served as Director of Medicinal Chemistry at Dunad Therapeutics from July 2022 to July 2023. Prior to this, Barry was the Principal Medicinal Chemist at Sitryx and held the position of Senior Scientist II at Sosei Heptares, where leadership included overseeing a team on a GPCR project. Earlier roles at AstraZeneca R&D Charnwood and Astra Charnwood involved significant contributions to numerous respiratory and inflammation projects, including co-inventorship on multiple patents and participation in the discovery of Brilinta. Barry's academic background includes a BSc Hons. in Chemistry from the University of Southampton and a PG Cert. in Intellectual Property from Bournemouth University, achieved with distinction.